Nicotine Regulation for Dual Users of E-cigarettes and Cigarettes
Launched by UNIVERSITY OF VERMONT · Sep 23, 2024
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how changes in nicotine levels in cigarettes affect adults who use both e-cigarettes and regular cigarettes, a group often referred to as dual users. Researchers want to understand if lowering the nicotine in cigarettes could help these individuals smoke less and rely more on e-cigarettes, especially since e-cigarettes are considered a less harmful option. The trial will look at how much people smoke, their dependence on cigarettes, and their exposure to harmful substances over 12 weeks.
To participate, you need to be at least 21 years old and regularly use tobacco products. If you are pregnant, trying to become pregnant, or nursing, you won’t be able to take part in this study. Participants will be assigned to different groups to try either normal or very low nicotine cigarettes and high or low nicotine e-cigarettes. This will help researchers see how these different nicotine levels affect smoking behaviors. The findings could provide important insights into how to improve public health strategies around tobacco use.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Regular use of tobacco
- • 21 year of age or older
- • Speak, comprehend and read English well enough to complete study procedures
- Exclusion Criteria:
- • Pregnant, trying to become pregnant, or nursing
- • Under the age of 21
- • Health conditions that could undermine ability to complete the study
About University Of Vermont
The University of Vermont (UVM) is a leading academic institution known for its commitment to advancing healthcare through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, UVM leverages its diverse expertise in medicine, public health, and biomedical sciences to conduct cutting-edge clinical studies. The university aims to translate scientific findings into effective treatments and interventions, ultimately improving patient outcomes and contributing to the broader medical community. UVM's research facilities and access to a wide patient population support its mission to foster a culture of inquiry and excellence in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Burlington, Vermont, United States
Providence, Rhode Island, United States
Patients applied
Trial Officials
Elias Klemperer, PhD
Principal Investigator
University of Vermont
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported